NFO Alert: ICICI Prudential Mutual Fund Launches ICICI Pru Nifty Pharma ETF

ICICI Prudential Mutual Fund has opened the new fund offer (NFO) for ICICI Pru Nifty Pharma ETF on October 12, 2026. The offer closes on October 19, 2026.  

The scheme falls under the equity sectoral-pharma category and is structured as an open-ended exchange-traded fund (ETF). 

The minimum investment amount is ₹1,000. The scheme offers a Growth plan, has no specified lock-in period, and carries no exit load. 

Investment Objective and Benchmark 

The scheme aims to generate returns, before expenses, that closely match the total returns of its underlying index, subject to tracking errors. Its benchmark is the NIFTY Pharma Total Returns Index (TRI). 

The fund's performance will be measured against this index. Differences between the scheme's returns and the benchmark may arise from tracking errors and the expenses associated with managing the fund. 

Very High-Risk Rating 

The scheme has been assigned a 'Very High' risk rating on its riskometer. It belongs to the sectoral-pharma category, which focuses on the pharmaceutical segment of the equity market. 

Unlike diversified equity schemes that invest across different sectors, a pharma-focused fund's performance is linked to the stocks covered by its underlying index. Movements in the pharmaceutical sector can therefore affect its returns. 

Fund Managers and Other Details 

Ashwini Jemin Bharucha, Nishit Patel, and Venus Ahuja have been named as the fund managers. ICICI Prudential Mutual Fund is the fund house offering the scheme. 

The ETF follows an index-based investment strategy, with its stated objective centred on matching the benchmark's total returns before expenses. The scheme is open-ended, with no specified lock-in period and a nil exit load. 

Read More: Parag Parikh Flexi Cap Fund Adds 13 Stocks in September, Including DLF, Bharti Airtel and Indus Towers! 

Conclusion 

The ICICI Pru Nifty Pharma ETF NFO is open from October 12 to October 19, 2026. The minimum investment is ₹1,000, the benchmark is the NIFTY Pharma TRI, and the scheme carries a Very High-risk rating. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Mutual Fund Investments are subject to market risks, read all the related documents carefully before investing.